Prometic Life Scienc (PFSCF) 2.1963 $PFSCF
The K2 Principal Fund L.P. acquires common shares in the capital of Telesta Thereapeutics Inc.
CNW Group - Mon Aug 29, 6:53AM CDT
The K2 Principal Fund L.P. ("K2"
announces that it acquired ownership of an aggregate of 18,019,500 common shares (the "Shares" in the capital Telesta Thereapeutics Inc. ("Telesta". Following the acquisition K2 owns 18,019,500 Shares, which represent approximately 5.94% of the issued and outstanding Shares of Telesta, and 697,500 common share purchase warrants. K2 acquired beneficial ownership of the Shares after Prometic Life Sciences Inc. announced that it intended to commence an offer to acquire all of the issued and outstanding Shares of Telesta on August 24, 2016.
Telesta Therapeutics Announces Execution of a Binding Purchase Agreement from ProMetic Life Sciences Inc.
PR Newswire - Wed Aug 24, 5:00AM CDT
Telesta Therapeutics Inc. (TSX: TST) (PNK: BNHLF) today announced that it has executed a binding Agreement, subject to shareholder approval, to be acquired by ProMetic Life Sciences Inc. for consideration of $0.14/Telesta share, payable in freely tradable shares of ProMetic Life Sciences (TSX: PLI). The actual number of ProMetic shares payable per Telesta common share, will be calculated based on the 5-day volume-weighted average price of ProMetic shares, for the 5 days immediately preceding the date on which the Court ordered plan of arrangement becomes effective if shareholders vote to approve this transaction.
TST.TO: 0.14 (+0.01), PLI.TO: 2.80 (-0.04)
ProMetic announces agreement to acquire Telesta Therapeutics Inc. in all share transaction
PR Newswire - Wed Aug 24, 5:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" announced today that it has entered into a binding agreement (the "Agreement" for the acquisition of Telesta Therapeutics, Inc, ("Telesta" by way of a plan of arrangement under the Canada Business Corporations Act (the "Acquisition".
PLI.TO: 2.80 (-0.04)
ProMetic reports second quarter 2016 highlights and financial results
CNW Group - Thu Aug 11, 3:56PM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" today reported revenues of $3.3 million for the second quarter ended June 30, 2016 compared to $2.9 million for the second quarter ended June 30, 2015 and total revenues of $8.5 million for the first half of 2016 compared to $4.8 million for the first half of 2015.
PLI.TO: 2.80 (-0.04)
Prometic completes patients' enrolment in pivotal plasminogen phase 2/3 clinical trial
CNW Group - Thu Aug 11, 5:15AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" announced today that it has completed enrolment of the congenital plasminogen deficient patients in its pivotal phase 2/3 clinical trial required for the accelerated regulatory approval pathway with the Food and Drug Administration ("FDA".
PLI.TO: 2.80 (-0.04)
ProMetic Completes Adult Patients' Enrolment in Pivotal IVIG Phase 3 Clinical Trial
CNW Group - Tue Aug 09, 5:30AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" announced today that it has completed the enrolment of the adult patient population (50 adult patients) in its pivotal IVIG phase III clinical trial for the treatment of primary immunodeficiency diseases ("PIDD".
PLI.TO: 2.80 (-0.04)
Prometic to report its second quarter 2016 financial results and hold conference call / webcast
CNW Group - Tue Aug 02, 9:49AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" announced today that it will report its financial results for the second quarter ended June 30, 2016 on Thursday August 11, 2016 after market close.
PLI.TO: 2.80 (-0.04)
ProMetic's plasminogen granted Fast Track designation by the US FDA
CNW Group - Mon Jun 13, 5:30AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" reported today that the U.S. Food and Drug Administration (FDA) has granted a Fast Track designation to ProMetic for its plasminogen drug candidate, currently in a phase 2/3 clinical trial in patients suffering from congenital Plasminogen deficiency.
PLI.TO: 2.80 (-0.04)
ProMetic to present new data on how PBI-4050 keeps pancreatic beta cells alive at the American Diabetic Association's upcoming annual meeting
CNW Group - Thu Jun 09, 6:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" reported today that Dr. Lyne Gagnon, Vice-President of Preclinical R&D at ProMetic will be giving an oral presentation at the American Diabetic Association's upcoming annual meeting on PBI-4050's effect on keeping insulin-producing pancreatic beta cells alive.
PLI.TO: 2.80 (-0.04)
ProMetic announces closing of $60 million bought deal offering of common shares
CNW Group - Wed May 25, 8:54AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF)("ProMetic" or the "Corporation" closed today its previously announced bought deal public offering of common shares in the capital of the Corporation (the "Offering" through a syndicate of underwriters led by RBC Capital Markets and Canaccord Genuity Corp., and which included Scotiabank, CIBC Capital Markets, National Bank Financial Inc., Paradigm Capital Inc. and Beacon Securities Limited (collectively, the "Underwriters". ProMetic issued 19,400,000 common shares of the Corporation in connection with the Offering at a price of $3.10 per share for aggregate gross proceeds of $60,140,000. In consideration for the services rendered by the Underwriters under the Offering, the Underwriters received a cash commission representing 5% of the gross proceeds of the Offering.
PLI.TO: 2.80 (-0.04)
Health Canada authorizes ProMetic to proceed with its PBI-4050 clinical trial in patients with cystic fibrosis
CNW Group - Wed May 18, 6:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" today reported that it had been approved to commence the clinical trial of its orally active anti-fibrotic lead drug candidate, PBI-4050, in patients suffering from cystic fibrosis ("CF", following the CTA clearance by Health Canada. The objectives of this 24 week randomized, double-blind, and placebo-controlled Phase 2 study includes the evaluation of the effects of PBI-4050 on pancreatic and lung function in 90 CF patients.
PLI.TO: 2.80 (-0.04)
Global Emphysema Pipeline Report 2016 - Review of Abeona Therapeutics, Angion Biomedica, ProMetic Life Sciences & rEVO Biologics & Their Drug Profiles - Research and Markets
BusinessWire - Fri May 13, 5:08AM CDT
Research and Markets has announced the addition of the "Emphysema - Pipeline Review, H1 2016" report to their offering.
RBIO: (), ABEO: 4.20 (-0.11)
ProMetic Reports its First Quarter 2016 Highlights and Financial Results
CNW Group - Thu May 12, 3:59PM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" today reported revenues of $5.2 million for the first quarter ended March 31, 2016 compared to $1.9 million for the first quarter ended March 31, 2015.
PLI.TO: 2.80 (-0.04)
Positive response in kidney and urinary tract to ProMetic's plasminogen treatment in a plasminogen deficient patient under an expanded access (compassionate use) protocol in the USA
CNW Group - Wed May 11, 5:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" announced today that the plasminogen deficient patient treated under a compassionate use IND in the USA has shown an additional significant positive response to the treatment; in this case, in his kidney and urinary tract. The Corporation has previously reported the rapid healing of this patient's multiple 4 month old surgical wounds on his hand.
PLI.TO: 2.80 (-0.04)
Prometic announces successful treatment of a plasminogen-deficient patient under an expanded access (compassionate use) protocol in the USA
CNW Group - Tue May 03, 5:45AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" announced today the successful treatment of another plasminogen deficient patient, in the USA, under a compassionate use IND.
PLI.TO: 2.80 (-0.04)
ProMetic confirms PBI-4050's Anti-Fibrotic Effect in Nash Model and on Human Hepatic Stellate Cells
CNW Group - Thu Apr 14, 6:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" presented today new data at the 2016 European Association for the Study of the Liver (EASL)'s 51(st) Annual Meeting - The International Liver Congress (ILC) in Spain.
PLI.TO: 2.80 (-0.04)
ProMetic reports its 2015 fourth quarter and year end highlights and financial results
CNW Group - Wed Mar 30, 4:42PM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" today reported revenues of $14.1 million and total revenues of $24.5 million for the fourth quarter and year ended December 31, 2015 respectively. This compares to revenues of $10.5 million and $23.0 million for the fourth quarter and year ended December 31, 2014 respectively.
PLI.TO: 2.80 (-0.04)
ProMetic confirms PBI-4050's positive effects on novel biomarkers in patients suffering from metabolic syndrome and Type 2 diabetes
PR Newswire - Tue Mar 22, 5:30AM CDT
-- Statistically significant decrease in novel biomarkers associated with a high risk of cardiovascular events
PLI.TO: 2.80 (-0.04)
The K2 Principal Fund L.P. acquires common shares in the capital of Telesta Thereapeutics Inc.
CNW Group - Mon Aug 29, 6:53AM CDT
The K2 Principal Fund L.P. ("K2"
announces that it acquired ownership of an aggregate of 18,019,500 common shares (the "Shares" in the capital Telesta Thereapeutics Inc. ("Telesta". Following the acquisition K2 owns 18,019,500 Shares, which represent approximately 5.94% of the issued and outstanding Shares of Telesta, and 697,500 common share purchase warrants. K2 acquired beneficial ownership of the Shares after Prometic Life Sciences Inc. announced that it intended to commence an offer to acquire all of the issued and outstanding Shares of Telesta on August 24, 2016. Telesta Therapeutics Announces Execution of a Binding Purchase Agreement from ProMetic Life Sciences Inc.
PR Newswire - Wed Aug 24, 5:00AM CDT
Telesta Therapeutics Inc. (TSX: TST) (PNK: BNHLF) today announced that it has executed a binding Agreement, subject to shareholder approval, to be acquired by ProMetic Life Sciences Inc. for consideration of $0.14/Telesta share, payable in freely tradable shares of ProMetic Life Sciences (TSX: PLI). The actual number of ProMetic shares payable per Telesta common share, will be calculated based on the 5-day volume-weighted average price of ProMetic shares, for the 5 days immediately preceding the date on which the Court ordered plan of arrangement becomes effective if shareholders vote to approve this transaction.
TST.TO: 0.14 (+0.01), PLI.TO: 2.80 (-0.04)
ProMetic announces agreement to acquire Telesta Therapeutics Inc. in all share transaction
PR Newswire - Wed Aug 24, 5:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
announced today that it has entered into a binding agreement (the "Agreement" for the acquisition of Telesta Therapeutics, Inc, ("Telesta" by way of a plan of arrangement under the Canada Business Corporations Act (the "Acquisition". PLI.TO: 2.80 (-0.04)
ProMetic reports second quarter 2016 highlights and financial results
CNW Group - Thu Aug 11, 3:56PM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
today reported revenues of $3.3 million for the second quarter ended June 30, 2016 compared to $2.9 million for the second quarter ended June 30, 2015 and total revenues of $8.5 million for the first half of 2016 compared to $4.8 million for the first half of 2015. PLI.TO: 2.80 (-0.04)
Prometic completes patients' enrolment in pivotal plasminogen phase 2/3 clinical trial
CNW Group - Thu Aug 11, 5:15AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
announced today that it has completed enrolment of the congenital plasminogen deficient patients in its pivotal phase 2/3 clinical trial required for the accelerated regulatory approval pathway with the Food and Drug Administration ("FDA". PLI.TO: 2.80 (-0.04)
ProMetic Completes Adult Patients' Enrolment in Pivotal IVIG Phase 3 Clinical Trial
CNW Group - Tue Aug 09, 5:30AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
announced today that it has completed the enrolment of the adult patient population (50 adult patients) in its pivotal IVIG phase III clinical trial for the treatment of primary immunodeficiency diseases ("PIDD". PLI.TO: 2.80 (-0.04)
Prometic to report its second quarter 2016 financial results and hold conference call / webcast
CNW Group - Tue Aug 02, 9:49AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
announced today that it will report its financial results for the second quarter ended June 30, 2016 on Thursday August 11, 2016 after market close. PLI.TO: 2.80 (-0.04)
ProMetic's plasminogen granted Fast Track designation by the US FDA
CNW Group - Mon Jun 13, 5:30AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
reported today that the U.S. Food and Drug Administration (FDA) has granted a Fast Track designation to ProMetic for its plasminogen drug candidate, currently in a phase 2/3 clinical trial in patients suffering from congenital Plasminogen deficiency. PLI.TO: 2.80 (-0.04)
ProMetic to present new data on how PBI-4050 keeps pancreatic beta cells alive at the American Diabetic Association's upcoming annual meeting
CNW Group - Thu Jun 09, 6:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
reported today that Dr. Lyne Gagnon, Vice-President of Preclinical R&D at ProMetic will be giving an oral presentation at the American Diabetic Association's upcoming annual meeting on PBI-4050's effect on keeping insulin-producing pancreatic beta cells alive. PLI.TO: 2.80 (-0.04)
ProMetic announces closing of $60 million bought deal offering of common shares
CNW Group - Wed May 25, 8:54AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF)("ProMetic" or the "Corporation"
closed today its previously announced bought deal public offering of common shares in the capital of the Corporation (the "Offering" through a syndicate of underwriters led by RBC Capital Markets and Canaccord Genuity Corp., and which included Scotiabank, CIBC Capital Markets, National Bank Financial Inc., Paradigm Capital Inc. and Beacon Securities Limited (collectively, the "Underwriters". ProMetic issued 19,400,000 common shares of the Corporation in connection with the Offering at a price of $3.10 per share for aggregate gross proceeds of $60,140,000. In consideration for the services rendered by the Underwriters under the Offering, the Underwriters received a cash commission representing 5% of the gross proceeds of the Offering. PLI.TO: 2.80 (-0.04)
Health Canada authorizes ProMetic to proceed with its PBI-4050 clinical trial in patients with cystic fibrosis
CNW Group - Wed May 18, 6:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
today reported that it had been approved to commence the clinical trial of its orally active anti-fibrotic lead drug candidate, PBI-4050, in patients suffering from cystic fibrosis ("CF", following the CTA clearance by Health Canada. The objectives of this 24 week randomized, double-blind, and placebo-controlled Phase 2 study includes the evaluation of the effects of PBI-4050 on pancreatic and lung function in 90 CF patients. PLI.TO: 2.80 (-0.04)
Global Emphysema Pipeline Report 2016 - Review of Abeona Therapeutics, Angion Biomedica, ProMetic Life Sciences & rEVO Biologics & Their Drug Profiles - Research and Markets
BusinessWire - Fri May 13, 5:08AM CDT
Research and Markets has announced the addition of the "Emphysema - Pipeline Review, H1 2016" report to their offering.
RBIO: (), ABEO: 4.20 (-0.11)
ProMetic Reports its First Quarter 2016 Highlights and Financial Results
CNW Group - Thu May 12, 3:59PM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
today reported revenues of $5.2 million for the first quarter ended March 31, 2016 compared to $1.9 million for the first quarter ended March 31, 2015. PLI.TO: 2.80 (-0.04)
Positive response in kidney and urinary tract to ProMetic's plasminogen treatment in a plasminogen deficient patient under an expanded access (compassionate use) protocol in the USA
CNW Group - Wed May 11, 5:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
announced today that the plasminogen deficient patient treated under a compassionate use IND in the USA has shown an additional significant positive response to the treatment; in this case, in his kidney and urinary tract. The Corporation has previously reported the rapid healing of this patient's multiple 4 month old surgical wounds on his hand. PLI.TO: 2.80 (-0.04)
Prometic announces successful treatment of a plasminogen-deficient patient under an expanded access (compassionate use) protocol in the USA
CNW Group - Tue May 03, 5:45AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
announced today the successful treatment of another plasminogen deficient patient, in the USA, under a compassionate use IND. PLI.TO: 2.80 (-0.04)
ProMetic confirms PBI-4050's Anti-Fibrotic Effect in Nash Model and on Human Hepatic Stellate Cells
CNW Group - Thu Apr 14, 6:00AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
presented today new data at the 2016 European Association for the Study of the Liver (EASL)'s 51(st) Annual Meeting - The International Liver Congress (ILC) in Spain. PLI.TO: 2.80 (-0.04)
ProMetic reports its 2015 fourth quarter and year end highlights and financial results
CNW Group - Wed Mar 30, 4:42PM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"
today reported revenues of $14.1 million and total revenues of $24.5 million for the fourth quarter and year ended December 31, 2015 respectively. This compares to revenues of $10.5 million and $23.0 million for the fourth quarter and year ended December 31, 2014 respectively. PLI.TO: 2.80 (-0.04)
ProMetic confirms PBI-4050's positive effects on novel biomarkers in patients suffering from metabolic syndrome and Type 2 diabetes
PR Newswire - Tue Mar 22, 5:30AM CDT
-- Statistically significant decrease in novel biomarkers associated with a high risk of cardiovascular events
PLI.TO: 2.80 (-0.04)
